Ibogaine Development Advances Amid Safety Warnings

A federal initiative seeks to accelerate the creation of psychedelic-based treatments, including ibogaine for psychiatric conditions. However, medical professionals are advised to consider significant safety concerns, such as the risk of fatal cardiac arrhythmias. Much of the existing data on ibogaine comes from unregulated treatment environments, though the FDA has authorized a phase 1 trial for a derivative.